Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Konrad Hermann Stopsack, M.D.

Title
Institution
Department
Address

Biography
University of Freiburg, Freiburg, GermanyMD, Dr. med.06/2013Medicine
Harvard School of Public Health, Boston, MAMPH05/2014Biostatistics and Epidemiology
Mayo Clinic, Rochester, MNBoard certification06/2017Internal Medicine (Residency)
Memorial Sloan Kettering Cancer Center, New York, NYcurrentCancer Epidemiology (Postdoctoral training)

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. 17YOUN16 (Stopsack)
    Prostate Cancer Foundation
    Young Investigator Award: Intratumoral cholesterol metabolism to guide prostate cancer therapy
    Role: PI
  2. Challenge Award (Kantoff)
    Prostate Cancer Foundation
    Clonal hematopoiesis in prostate cancer
    Role: Co-Investigator
  3. Traditional Bridge Grant (Amon/Mucci)
    Harvard–MIT Bridge Program
    Credentialing aneuploidy as a prognostic biomarker in prostate cancer
    Role: Co-Investigator
  4. W81XWH-18-1-0330 (Stopsack)
    Department of Defense, Congressionally Directed Medical Research Program
    Early-Investigator Research Award: Cholesterol synthesis and statin therapy in prostate cancer
    Role: PI

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Stopsack KH. Reply to Johann S. de Bono, Maha Hussain, and Jinyu Kang's Letter to the Editor re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024. Eur Urol. 2020 Dec 22. PMID: 33358233.
    Citations:    
  2. Chakraborty G, Khan Patail N, Hirani R, Nandakumar S, Mazzu YZ, Yoshikawa Y, Atiq MO, Jehane L, Stopsack KH, Lee GM, Abida W, Morris MJ, Mucci LA, Danila DC, Kantoff PW. Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered prostate tumors. Clin Cancer Res. 2020 Dec 17. PMID: 33334906.
    Citations:    
  3. Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, Patel M, Berthon A, Syed A, Yabe M, Coombs CC, Caltabellotta NM, Walsh M, Offit K, Stadler Z, Mandelker D, Schulman J, Patel A, Philip J, Bernard E, Gundem G, Ossa JEA, Levine M, Martinez JSM, Farnoud N, Glodzik D, Li S, Robson ME, Lee C, Pharoah PDP, Stopsack KH, Spitzer B, Mantha S, Fagin J, Boucai L, Gibson CJ, Ebert BL, Young AL, Druley T, Takahashi K, Gillis N, Ball M, Padron E, Hyman DM, Baselga J, Norton L, Gardos S, Klimek VM, Scher H, Bajorin D, Paraiso E, Benayed R, Arcila ME, Ladanyi M, Solit DB, Berger MF, Tallman M, Garcia-Closas M, Chatterjee N, Diaz LA, Levine RL, Morton LM, Zehir A, Papaemmanuil E. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020 11; 52(11):1219-1226. PMID: 33106634.
    Citations:    
  4. Hurwitz LM, Agalliu I, Albanes D, Barry KH, Berndt SI, Cai Q, Chen C, Cheng I, Genkinger JM, Giles GG, Huang J, Joshu CE, Key TJ, Knutsen S, Koutros S, Langseth H, Li SX, MacInnis RJ, Markt SC, Penney KL, Perez-Cornago A, Rohan TE, Smith-Warner SA, Stampfer MJ, Stopsack KH, Tangen CM, Travis RC, Weinstein SJ, Wu L, Jacobs EJ, Mucci LA, Platz EA, Cook MB. Recommended definitions of aggressive prostate cancer for etiologic epidemiologic research. J Natl Cancer Inst. 2020 Oct 03. PMID: 33010161.
    Citations:    Fields:    
  5. Stopsack KH. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. 2020 Oct 01. PMID: 33012578.
    Citations:    Fields:    
  6. Stopsack KH, Huang Y, Tyekucheva S, Gerke TA, Bango C, Elfandy H, Bowden M, Penney KL, Roberts TM, Parmigiani G, Kantoff PW, Mucci LA, Loda M. Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation. Clin Cancer Res. 2020 Nov 15; 26(22):5903-5913. PMID: 32913135.
    Citations:    Fields:    
  7. Drago JZ, Gönen M, Thanarajasingam G, Sacks CA, Morris MJ, Kantoff PW, Stopsack KH. Inferences about drug safety in phase 3 trials in oncology: Examples from advanced prostate cancer. J Natl Cancer Inst. 2020 Aug 28. PMID: 32857839.
    Citations:    Fields:    
  8. Stopsack KH, Gerke T, Zareba P, Pettersson A, Chowdhury D, Ebot EM, Flavin R, Finn S, Kantoff PW, Stampfer MJ, Loda M, Fiorentino M, Mucci LA. Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. Carcinogenesis. 2020 Jul 14; 41(7):904-908. PMID: 32556091.
    Citations:    Fields:    
  9. Fankhauser CD, Penney KL, Gonzalez-Feliciano AG, Clarke NW, Hermanns T, Stopsack KH, Fiorentino M, Loda M, Mahal B, Gerke TA, Preston MA, Mucci LA. Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. Eur Urol. 2020 Oct; 78(4):637-639. PMID: 32624279.
    Citations:    Fields:    
  10. Feng X, Song M, Preston MA, Ma W, Hu Y, Pernar CH, Stopsack KH, Ebot EM, Fu BC, Zhang Y, Li N, Dai M, Liu L, Giovannucci EL, Mucci LA. The association of diabetes with risk of prostate cancer defined by clinical and molecular features. Br J Cancer. 2020 Aug; 123(4):657-665. PMID: 32467600.
    Citations:    Fields:    
  11. Nguyen B, Mota JM, Nandakumar S, Stopsack KH, Weg E, Rathkopf D, Morris MJ, Scher HI, Kantoff PW, Gopalan A, Zamarin D, Solit DB, Schultz N, Abida W. Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. Eur Urol. 2020 Nov; 78(5):671-679. PMID: 32317181.
    Citations:    Fields:    
  12. Mota JM, Barnett E, Nauseef JT, Nguyen B, Stopsack KH, Wibmer A, Flynn JR, Heller G, Danila DC, Rathkopf D, Slovin S, Kantoff PW, Scher HI, Morris MJ, Schultz N, Solit DB, Abida W. Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. JCO Precis Oncol. 2020; 4:355-366. PMID: 32856010.
    Citations:    
  13. Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? Cancer Discov. 2020 06; 10(6):779-782. PMID: 32276929.
    Citations: 37     Fields:    Translation:HumansCellsPHPublic Health
  14. Stopsack KH, Nandakumar S, Wibmer AG, Haywood S, Weg ES, Barnett ES, Kim CJ, Carbone EA, Vasselman SE, Nguyen B, Hullings MA, Scher HI, Morris MJ, Solit DB, Schultz N, Kantoff PW, Abida W. Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. Clin Cancer Res. 2020 Jul 01; 26(13):3230-3238. PMID: 32220891.
    Citations: 1     Fields:    
  15. Chakraborty G, Armenia J, Mazzu YZ, Nandakumar S, Stopsack KH, Atiq MO, Komura K, Jehane L, Hirani R, Chadalavada K, Yoshikawa Y, Khan NA, Chen Y, Abida W, Mucci LA, Lee GM, Nanjangud GJ, Kantoff PW. Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression. Clin Cancer Res. 2020 04 15; 26(8):2047-2064. PMID: 31796516.
    Citations: 1     Fields:    
  16. Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Ahearn TU, Gerke TA, Downer MK, Rider JR, Freedland SJ, Lotan TL, Kantoff PW, Platz EA, Loda M, Stampfer MJ, Giovannucci E, Sweeney CJ, Finn SP, Mucci LA. Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):1086-1093. PMID: 31754047.
    Citations:    Fields:    
  17. Stopsack KH, Cerhan JR. Cumulative Doses of Ionizing Radiation From Computed Tomography: A Population-Based Study. Mayo Clin Proc. 2019 10; 94(10):2011-2021. PMID: 31248696.
    Citations:    Fields:    Translation:Humans
  18. Stopsack KH, Whittaker CA, Gerke TA, Loda M, Kantoff PW, Mucci LA, Amon A. Aneuploidy drives lethal progression in prostate cancer. Proc Natl Acad Sci U S A. 2019 06 04; 116(23):11390-11395. PMID: 31085648.
    Citations: 5     Fields:    Translation:HumansCells
  19. Khan NA, Stopsack KH, Allott EH, Gerke T, Giovannucci EL, Mucci LA, Kantoff PW. Intratumoral Sterol-27-Hydroxylase (CYP27A1) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 06; 28(6):1052-1058. PMID: 30867220.
    Citations: 2     Fields:    Translation:HumansCells
  20. Stopsack KH, Gerke T, Tyekucheva S, Mazzu YZ, Lee GM, Chakraborty G, Abida W, Mucci LA, Kantoff PW. Low Expression of the Androgen-Induced Tumor Suppressor Gene PLZF and Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 04; 28(4):707-714. PMID: 30602500.
    Citations: 3     Fields:    Translation:HumansCells
  21. Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH, Zadra G, Penney KL, Mosquera JM, Tyekucheva S, Mucci LA, Barbieri C, Loda M. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Mol Cancer Res. 2019 02; 17(2):446-456. PMID: 30333152.
    Citations: 4     Fields:    Translation:HumansAnimals
  22. Pernar CH, Ebot EM, Pettersson A, Graff RE, Giunchi F, Ahearn TU, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Stopsack KH, Gazeeva E, Lis RT, Parmigiani G, Rimm EB, Finn SP, Giovannucci EL, Fiorentino M, Mucci LA. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. Eur Urol. 2019 07; 76(1):33-40. PMID: 30301696.
    Citations: 3     Fields:    Translation:Humans
  23. Xie W, Stopsack KH, Drouin SJ, Fu H, Pomerantz MM, Mucci LA, Lee GM, Kantoff PW. Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival. Prostate. 2019 01; 79(1):73-80. PMID: 30141208.
    Citations: 1     Fields:    Translation:Humans
  24. Stopsack KH, Gonzalez-Feliciano AG, Peisch SF, Downer MK, Gage RA, Finn S, Lis RT, Graff RE, Pettersson A, Pernar CH, Loda M, Kantoff PW, Ahearn TU, Mucci LA. A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev. 2018 10; 27(10):1231-1233. PMID: 30108097.
    Citations:    Fields:    Translation:Humans
  25. Stopsack KH, Ebot EM, Downer MK, Gerke TA, Rider JR, Kantoff PW, Mucci LA. Regular aspirin use and gene expression profiles in prostate cancer patients. Cancer Causes Control. 2018 Aug; 29(8):775-784. PMID: 29915914.
    Citations:    Fields:    Translation:HumansCells
  26. Brauner A, Alvendal C, Chromek M, Stopsack KH, Ehrström S, Schröder JM, Bohm-Starke N. Psoriasin, a novel anti-Candida albicans adhesin. J Mol Med (Berl). 2018 06; 96(6):537-545. PMID: 29736603.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  27. Stopsack KH, Gerke TA, Andrén O, Andersson SO, Giovannucci EL, Mucci LA, Rider JR. Cholesterol uptake and regulation in high-grade and lethal prostate cancers. Carcinogenesis. 2017 08 01; 38(8):806-811. PMID: 28595267.
    Citations: 11     Fields:    Translation:Humans
  28. Bormann T, Stopsack KH, Mader I, Weiller C, Rijntjes M. A formal analysis of alexia in persistent aura and a comparison to acquired pure alexia. Neurocase. 2017 Feb; 23(1):60-64. PMID: 28376693.
    Citations:    Fields:    Translation:Humans
  29. Stopsack KH, Greenberg AJ, Mucci LA. Common medications and prostate cancer mortality: a review. World J Urol. 2017 Jun; 35(6):875-882. PMID: 27492013.
    Citations: 4     Fields:    Translation:Humans
  30. Weidler S, Stopsack KH, Hammermann J, Sommerburg O, Mall MA, Hoffmann GF, Kohlmüller D, Okun JG, Macek M, Votava F, Krulišová V, Balašcaková M, Skalická V, Lee-Kirsch MA, Stopsack M. A product of immunoreactive trypsinogen and pancreatitis-associated protein as second-tier strategy in cystic fibrosis newborn screening. J Cyst Fibros. 2016 11; 15(6):752-758. PMID: 27461140.
    Citations: 4     Fields:    Translation:HumansPHPublic Health
  31. Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, Sesso HD, Andersson SO, Andrén O, Cerhan JR, Giovannucci EL, Mucci LA, Rider JR. Cholesterol Metabolism and Prostate Cancer Lethality. Cancer Res. 2016 08 15; 76(16):4785-90. PMID: 27325648.
    Citations: 11     Fields:    Translation:Humans
  32. Kekre N, Mak KS, Stopsack KH, Binder M, Ishii K, Brånvall E, Cutler CS. Impact of HLA-Mismatch in Unrelated Donor Hematopoietic Stem Cell Transplantation: A Meta-Analysis. Am J Hematol. 2016 06; 91(6):551-5. PMID: 26927727.
    Citations: 7     Fields:    Translation:Humans
  33. Stopsack KH, Vinod Shah M. Bilateral Foot Gangrene. JAMA Oncol. 2016 Mar; 2(3):387-8. PMID: 26847423.
    Citations:    Fields:    Translation:Humans
  34. Stopsack KH, Ziehr DR, Rider JR, Giovannucci EL. Metformin and prostate cancer mortality: a meta-analysis. Cancer Causes Control. 2016 Jan; 27(1):105-13. PMID: 26537119.
    Citations: 20     Fields:    Translation:Humans
  35. Ramos NL, Dzung DT, Stopsack K, Jankó V, Pourshafie MR, Katouli M, Brauner A. Characterisation of uropathogenic Escherichia coli from children with urinary tract infection in different countries. Eur J Clin Microbiol Infect Dis. 2011 Dec; 30(12):1587-93. PMID: 21509475.
    Citations: 7     Fields:    Translation:HumansCells
  36. Vogelberg C, Stensvold CR, Monecke S, Ditzen A, Stopsack K, Heinrich-Gräfe U, Pöhlmann C. Blastocystis sp. subtype 2 detection during recurrence of gastrointestinal and urticarial symptoms. Parasitol Int. 2010 Sep; 59(3):469-71. PMID: 20363362.
    Citations: 27     Fields:    Translation:HumansAnimals
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: SPH faculty should contact Faculty Affairs at facultyaffairshsph.harvard.edu).
Stopsack's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (134)
Explore
_
Co-Authors (32)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.